D&D Pharmatech 2hits limit-up on trial results; InBody sees growth potential in demand for body composition analysis

D&D Pharmatech 2026year 5month 27day, disclosed results from a clinical 2trial of its MASH (metabolic dysfunction-associated steatohepatitis) treatment. The company said it had achieved statistical significance in the 2trial. Shares closed at the daily limit-up immediately after the announcement. Trading in related biotech stocks became active following the announcement.

The release of D&D Pharmatech's 2trial results drew investor interest in the biotech sector that day. A surge in buying and selling was observed following the company's announcement. Some biotech stocks showed strong performance during the session. The release of clinical data acted as a key catalyst in the market.

InBody 2026year 5month 28day, said it expects demand for body composition analysis to increase, citing the expansion of the obesity management market. The company explained that demand for body composition analysis devices and services is expected to rise. The announcement is related to growing demand for health and weight management. Information on shipments of related products and sales performance can be confirmed through company announcements.

Flows related to AI infrastructure also emerged during the same period. 2026year 5month 27day, the AI infrastructure rally sent some systems integration (SI) stocks to the upper price limit at the same time. Trading was concentrated in several stocks in the sector. Reports said the active trading was linked to expectations of increased investment in AI infrastructure.

27day and 28day, volatility increased in biotech, healthcare, and AI infrastructure-related stocks over the two days. Official announcements from the respective companies directly affected their share prices. Investors should check for further company disclosures, detailed clinical trial data, and product shipment reports. Disclosures can be checked through each listed company’s disclosure system.